Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ELOSULFASE ALFA

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Mucopolysaccharidosis IVA (Morquio A) is a rare inherited metabolic disease caused by deficiency of the lysosomal enzyme N… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
2017
2017
PURPOSE Elosulfase alfa is an enzyme replacement therapy for the treatment of Morquio A syndrome (mucopolysaccharidosis IVA), a… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
2017
2017
BackgroundThis post hoc subanalysis examined outcomes in adult patients with Morquio A (mucopolysaccharidosis IVA) who received… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
2016
2016
Long-term efficacy and safety of elosulfase alfa enzyme replacement therapy were evaluated in Morquio A patients over 96weeks… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Review
2016
Review
2016
Mucopolysaccharidosis type IVA (MPS IVA or Morquio A) is an autosomal recessive lysosomal storage disease which results in a… Expand
  • table 1
Review
2016
Review
2016
  • C. Hendriksz
  • Expert review of clinical pharmacology
  • 2016
  • Corpus ID: 4113175
ABSTRACT Introduction: Morquio A syndrome is a rare, autosomal recessive, lysosomal storage disorder caused by a deficiency in… Expand
2015
2015
  • P. Harmatz
  • Clinical therapeutics
  • 2015
  • Corpus ID: 33758501
Lysosomal storage diseases arise because of genetic mutations that result in nonfunctioning or dysfunctional lysosomal enzymes… Expand
Review
2014
Review
2014
Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome, is an inherited, lysosomal storage disorder caused by… Expand